Resignation of Luis A. Aguilar as a Director
(b) Luis A. Aguilar resigned from the Board of Directors of MiMedx Group, Inc. (the “Company”) on September 19, 2019. Mr. Aguilar\’s resignation was not as a result of a disagreement with the Company.
On September 20, 2019, the Company issued a press release announcing the resignation of Luis A. Aguilar from the Company\’s Board of Directors. A copy of the press release is furnished as Exhibit 99.1 to this report.
(d) Exhibits
99.1 Press Release dated September 20, 2019.
MIMEDX GROUP, INC. Exhibit
EX-99.1 2 ex991aguilarpressrelease.htm PRESS RELEASE Exhibit Exhibit 99.1MiMedx Announces Resignation of Board MemberMr. Luis A. Aguilar Resigned Effective September 19,…
To view the full exhibit click here

About MIMEDX GROUP, INC. (NASDAQ:MDXG)

MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.